Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
This article was originally published in The Pink Sheet Daily
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
You may also be interested in...
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.